Alaunos Therapeutics Announces Early Data From Two Non-GLP DIO Mouse Studies Evaluating ALN1003 For Treating Obesity And Related Conditions

• The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model
• ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice
• Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing

FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT), an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). ALN1003 is an oral small-molecule drug being developed for a non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. We conducted two separate studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice maintained on a high-fat diet (60% of calories from fat). Highlights from these studies include dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, decreases in liver injury enzymes (ALT, AST and ALP) and other liver-related biomarker, and improvement in metabolic biomarkers (e.g., glucose and total cholesterol). Collectively, these findings suggest encouraging metabolic effects of ALN1003 in the DIO model.

These studies provide early signs of how the drug works and its potential safety profile that will help guide the Company's ongoing preclinical work and chemistry, manufacturing, and controls (CMC) initiatives.